
Gaurav Prakash M.D.
@DrGPrakash
Followers
4K
Following
14K
Media
505
Statuses
5K
Medical Oncologist, Prof, PGI-Chandigarh. Dedicated to help cancer patients & develop Medical Oncology at PGIMER, Chandigarh. Tweets personal. Likes 🚴♂️ & 🏃
India
Joined December 2011
How to read an HLA report?.A thread 🧵✍️on understating HLA typing for BMT. Key slides from my talk at #ISBMT Annual Meeting.(1/7) @IsbmtU @ASTCT @ASTCT_Journal @ISMPOofficial @ishbtHematology
12
127
314
Take the right catches in life. Drop the bad ones. #NoTobacco.
तंबाकू की लत सिर्फ़ आपको नहीं, बल्कि पूरे परिवार की सेहत को नुकसान पहुंचाती है!. अब समय है बदलाव का – स्वस्थ जीवन अपनाएं, तंबाकू से दूर रहें!. #SayNoToTobacco.#HealthForAll
0
1
4
RT @DrGPrakash: #Darvesh, #sufism .#watercolorpainting .A painting made by a leukemia transplant patient on day+3 of her BMT at #PGIMER #Ch….
0
4
0
I join Dr Ravi Vij from Washington University to discuss T-NHL and some of the challenges faced while treating patients with T-NHL in India. @My_Cancer_Haven @DrGPrakash .
0
1
6
RT @ISROSpaceflight: LIFTOFF of GSLV-F16 at 5:40 pm IST from Sriharikota, carrying the NASA-ISRO joint NISAR mission 🚀. #ISRO #GSLVF16 #NIS….
0
953
0
Less-is-more is an important question to answer, @Charanpreet_14 led this analysis and it paves way for a forward looking trial.
Excited to share our latest publication highlighting the use of a fixed, low dose of Nivolumab in patients with R/R Hodgkin Lymphoma #lymsm . Grateful to @DrGPrakash and @DrPMPGI for the mentorship.
0
0
2
RT @ShekharGupta: This is for sure the finest fight back ever in a SENA country for India. Will rank higher than 2002, Nottingham with Zahe….
0
85
0
PET CT and BM based composite MRD is a better tool for prognostication of MM. Recent paper from our group. @rudra09s025 👏.
🧵5 Key Takeaways from Our Study on Composite MRD in Myeloma ASCT👇.📍Published in Blood Cell Therapy (APBMT).1.🔍 Pre-ASCT cMRD negativity = better outcomes.→ 3-yr TTNT: 91% vs. 67% (p=0.027).2.📊 Pre-ASCT MRD more predictive than post-ASCT.→ Post-ASCT
2
1
7
RT @forallcurious: Mind=BLOWN🚨: Scientists have now found all of the DNA and RNA bases in meteorites . This means there's a possibili….
0
4K
0
With respect to cell therpay, this is an interesting space to watch. No leukopharesis or cytotoxic prep regimen needed for IN-VIVO CART Cell therpay. @IsbmtU.
1/ 🧪 The Era of In-Vivo CAR-T Has Arrived. No leukapheresis. No lymphodepletion. No 3-week manufacturing delay. Just a vial and a vein. EsoBiotech’s in-vivo BCMA CAR-T has shown deep responses in myeloma after a single infusion. Here’s why that matters 🧵
0
0
4
Painful visuals.
भारी बारिश 🌧️ के बाद केदारनाथ में प्राकृतिक झरनों में दिखी ये झकझोर देने वाली तस्वीर 😱. आख़िर इंसान है अपनी …… तो दिखायेगा 😡. #Kedarnath #Uttarakhand
0
1
6
RT @aiims_newdelhi: Proud moment for Bharat 🇮🇳! .@WHO has declared India as Trachoma-Free, eliminating a disease that once caused widespre….
0
300
0
Further analysis on HMA Ven treated younger patients and outcome of various post-CR options is underway and wil help to fill the void in this space. @DrGPrakash .@PGI_HematOnc.
0
1
7
RT @IndianTechGuide: 🚨 Indian astronaut is finally going to space after 41 years. 🇮🇳. #AxiomMission4 #axiom4mission
0
2K
0
RT @medoncodoc: Important data for LMIC and resource constrained setting from PGI Chandigarh!.@DrGPrakash @DrPMPGI . Ven 50 mg + Posa gener….
0
5
0
Our recent paper on Low dose Ven+Aza for AML induction . 'Key Points'.1. Low Dose Ven achieved similar Response & MRD negative rate as Ven400.2. Ven50 was better tolerated.3. Peak Plasma level with Ven50 was lower than Ven400.w.r.t. Ven for AML "Less may be enough".#Leusm.
📢 Now available online !.Full article : Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough. 👉 #asco2025 poster,
2
1
20
RT @rudra09s025: 📢 Now available online !.Full article : Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax….
0
27
0